Skip to main content
SpringerLink
Log in

Molecular Signatures of Bladder Cancer

  • Chapter
  • First Online:
Bladder Tumors:

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 789 Accesses

Abstract

Molecular signatures can be defined in many ways but are basically the characteristic features of the molecular composition of a cell or its surroundings. Crucial differences exist between normal and cancer cells that stem from discreet changes in specific genes that control tissue proliferation, apoptosis, invasion, as well as homeostasis (Harris 1996). There are a multitude of cancer related genes that have been discovered and implicated in the natural history of various malignancies. With our increased understanding of disease mechanisms and molecular techniques, the number of molecular signatures of cancer has increased exponentially with several signatures serving as both diagnostic and therapeutic targets.

In this chapter, we will explore molecular signatures of bladder cancer. During preparation of this section, we had several goals in mind. In addition to discussing molecular signatures of bladder cancer that are currently in use, it is important to be aware of those in development and foster critical thinking regarding signature investigation and bridging the gap between basic research and clinical application.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abdulamir AS, Hafidh RR, Kadhim HS et al (2009) Tumor markers of bladder cancer: the schistosomal bladder tumors versus non-schistosomal bladder tumors. J Exp Clin Cancer Res 28:27

    Article  PubMed  Google Scholar 

  • Altieri DC (2004) Molecular circuits of apoptosis regulation and cell division control: the survivin paradigm. J Cell Biochem 92:656

    Article  CAS  PubMed  Google Scholar 

  • Alvarez A, Lokeshwar VB (2007) Bladder cancer biomarkers: current developments and future implementation. Curr Opin Urol 17:341

    Article  PubMed  Google Scholar 

  • American cancer society: cancer facts and figures (2010)http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-026238.pdf

  • Araki M, Nieder AM, Manoharan M et al (2007) Lack of progress in early diagnosis of bladder cancer. Urology 69:270

    Article  PubMed  Google Scholar 

  • Atkinson S, Armstrong L (2008) Epigenetics in embryonic stem cells: regulation of pluripotency and differentiation. Cell Tissue Res 331:23

    Article  PubMed  Google Scholar 

  • Atlasi Y, Mowla SJ, Ziaee SA et al (2007) OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer. Int J Cancer 120:1598

    Article  CAS  PubMed  Google Scholar 

  • Babjuk M, Soukup V, Pesl M et al (2008) Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma. Urology 71:718

    Article  CAS  PubMed  Google Scholar 

  • Bennett A (2008) Telomerase and other novel approaches to bladder cancer detection. Clin Lab Sci 21:185

    PubMed  Google Scholar 

  • Bernstein BE, Meissner A, Lander ES (2007) The mammalian epigenome. Cell 128:669

    Article  CAS  PubMed  Google Scholar 

  • Bhatia A, Dey P, Kumar Y et al (2007) Expression of cytokeratin 20 in urine cytology smears: a potential marker for the detection of urothelial carcinoma. Cytopathology 18:84

    Article  CAS  PubMed  Google Scholar 

  • Black PC, Brown GA, Dinney CP (2006) Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer. J Clin Oncol 24:5528

    Article  CAS  PubMed  Google Scholar 

  • Blaveri E, Simko JP, Korkola JE et al (2005) Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res 11:4044

    Article  CAS  PubMed  Google Scholar 

  • Botteman MF, Pashos CL, Redaelli A et al (2003) The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21:1315

    Article  PubMed  Google Scholar 

  • Celis JE, Gromov P (2003) Proteomics in translational cancer research: toward an integrated approach. Cancer Cell 3:9

    Article  CAS  PubMed  Google Scholar 

  • Celis JE, Celis P, Palsdottir H et al (2002) Proteomic strategies to reveal tumor heterogeneity among urothelial papillomas. Mol Cell Proteomics 1:269

    Article  CAS  PubMed  Google Scholar 

  • Chan MW, Chan LW, Tang NL et al (2002) Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 8:464

    CAS  PubMed  Google Scholar 

  • Cong YS, Wright WE, Shay JW (2002) Human telomerase and its regulation. Microbiol Mol Biol Rev 66:407

    Article  CAS  PubMed  Google Scholar 

  • Davies B, Chen J, Modugno F et al (2005) Contribution of the prostate limits the usefulness of survivin for the detection of bladder cancer. J Urol 174:1767

    Article  PubMed  Google Scholar 

  • Denzinger S, Mohren K, Knuechel R et al (2006) Improved clonality analysis of multifocal bladder tumors by combination of histopathologic organ mapping, loss of heterozygosity, fluorescence in situ hybridization, and p53 analyses. Hum Pathol 37:143

    Article  CAS  PubMed  Google Scholar 

  • Di Carlo A, Terracciano D, Mariano A et al (2003) Role of cytokeratins, nuclear matrix proteins, Lewis antigen and epidermal growth factor receptor in human bladder tumors. Int J Oncol 23:757

    PubMed  Google Scholar 

  • Dominguez G, Silva J, Garcia JM et al (2003) Prevalence of aberrant methylation of p14ARF over p16INK4a in some human primary tumors. Mutat Res 530:9

    CAS  PubMed  Google Scholar 

  • Donat TL, Sakr W, Lehr JE et al (1996) Unique nuclear matrix protein alterations in head and neck squamous cell carcinomas: intermediate biomarker candidates. Otolaryngol Head Neck Surg 114:387

    Article  CAS  PubMed  Google Scholar 

  • Eissa S, Ali-Labib R, Swellam M et al (2007) Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine. Eur Urol 52:1388

    Article  CAS  PubMed  Google Scholar 

  • el-Deiry WS, Tokino T, Velculescu VE et al (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75:817

    Article  CAS  PubMed  Google Scholar 

  • Esteller M (2008) Epigenetics in cancer. N Engl J Med 358:1148

    Article  CAS  PubMed  Google Scholar 

  • Feinberg AP, Vogelstein B (1983) Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301:89

    Article  CAS  PubMed  Google Scholar 

  • Fradet Y (1996) Epidemiology of bladder cancer. In: Scardino P, Vogelzang NJ, Shipley WU, Coffey DS (eds) Comprehensive textbook of genitourinary oncology. Williams and Wilkins, Baltimore, MD, pp 298–304

    Google Scholar 

  • Fradet Y, Lockhard C (1997) Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt trade mark. Can J Urol 4:400

    PubMed  Google Scholar 

  • Fraga M, Garcia-Caballero T, Dominguez F et al (1993) Immunohistochemical location of prothymosin alpha in regenerating human hepatocytes and hepatocellular carcinomas. Virchows Arch A Pathol Anat Histopathol 423:449

    Article  CAS  PubMed  Google Scholar 

  • Fraga MF, Ballestar E, Villar-Garea A et al (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37:391

    Article  CAS  PubMed  Google Scholar 

  • Friedrich MG, Toma MI, Hellstern A et al (2003) Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer. BJU Int 92:911

    Article  CAS  PubMed  Google Scholar 

  • Getzenberg RH, Konety BR, Oeler TA et al (1996) Bladder cancer-associated nuclear matrix proteins. Cancer Res 56:1690

    CAS  PubMed  Google Scholar 

  • Golshani R, Lopez L, Estrella V et al (2008) Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44. Cancer Res 68:483

    Article  CAS  PubMed  Google Scholar 

  • Greger V, Passarge E, Hopping W et al (1989) Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum Genet 83:155

    Article  CAS  PubMed  Google Scholar 

  • Gromov PS, Ostergaard M, Gromova I et al (2002) Human proteomic databases: a powerful resource for functional genomics in health and disease. Prog Biophys Mol Biol 80:3

    Article  CAS  PubMed  Google Scholar 

  • Gudjonsson S, Isfoss BL, Hansson K et al (2008) The value of the UroVysion assay for surveillance of non-muscle-invasive bladder cancer. Eur Urol 54:402

    Article  PubMed  Google Scholar 

  • Hajdinjak T (2008) UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol 26:646

    CAS  PubMed  Google Scholar 

  • Halling KC, Kipp BR (2008) Bladder cancer detection using FISH (UroVysion assay). Adv Anat Pathol 15:279

    Article  CAS  PubMed  Google Scholar 

  • Halling KC, King W, Sokolova IA et al (2000) A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 164:1768

    Article  CAS  PubMed  Google Scholar 

  • Halling KC, King W, Sokolova IA et al (2002) A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol 167:2001

    Article  CAS  PubMed  Google Scholar 

  • Han M, Partin AW, Zahurak M et al (2003) Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169:517

    Article  PubMed  Google Scholar 

  • Hankey BF, Feuer EJ, Clegg LX et al (1999) Cancer surveillance series: interpreting trends in prostate cancer – part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 91:1017

    Article  CAS  PubMed  Google Scholar 

  • Harris CC (1996) p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology, and cancer risk assessment. Environ Health Perspect 104(Suppl 3):435

    Article  CAS  PubMed  Google Scholar 

  • He L, Hannon GJ (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5:522

    Article  CAS  PubMed  Google Scholar 

  • Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042

    Article  CAS  PubMed  Google Scholar 

  • Herman JG, Latif F, Weng Y et al (1994) Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 91:9700

    Article  CAS  PubMed  Google Scholar 

  • Herman JG, Merlo A, Mao L et al (1995) Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55:4525

    CAS  PubMed  Google Scholar 

  • Holliday R (1987) The inheritance of epigenetic defects. Science 238:163

    Article  CAS  PubMed  Google Scholar 

  • Huang W, Zhou X, Lefebvre V et al (2000) Phosphorylation of SOX9 by cyclic AMP-dependent protein kinase A enhances SOX9’s ability to transactivate a Col2a1 chondrocyte-specific enhancer. Mol Cell Biol 20:4149

    Article  CAS  PubMed  Google Scholar 

  • Jain KK (2008) Innovations, challenges and future prospects of oncoproteomics. Mol Oncol 2:153

    Article  PubMed  Google Scholar 

  • Johnson DE, Williams LT (1993) Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 60:1

    Article  CAS  PubMed  Google Scholar 

  • Jones PA, Taylor SM (1980) Cellular differentiation, cytidine analogs and DNA methylation. Cell 20:85

    Article  CAS  PubMed  Google Scholar 

  • Jovanovic M, Hadzi-Djokic J, Dzamic Z et al (2007) Evaluation of the Bard BTA-test in the diagnosis of upper urinary tract tumours. Acta Chir Iugosl 54:19

    Article  CAS  PubMed  Google Scholar 

  • Junker K, Wolf M, Schubert J (2005) Molecular clonal analysis of recurrent bladder cancer. Oncol Rep 14:319

    CAS  PubMed  Google Scholar 

  • Junker K, Fritsch T, Hartmann A et al (2006) Multicolor fluorescence in situ hybridization (M-FISH) on cells from urine for the detection of bladder cancer. Cytogenet Genome Res 114:279

    Article  CAS  PubMed  Google Scholar 

  • Kagan HM, Li W (2003) Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem 88:660

    Article  CAS  PubMed  Google Scholar 

  • Karran P (1996) Microsatellite instability and DNA mismatch repair in human cancer. Semin Cancer Biol 7:15

    Article  CAS  PubMed  Google Scholar 

  • Katayama M, Hino F, Odate Y et al (1989) Isolation and characterization of two monoclonal antibodies that recognize remote epitopes on the cell-binding domain of human fibronectin. Exp Cell Res 185:229

    Article  CAS  PubMed  Google Scholar 

  • Keesee SK, Meneghini MD, Szaro RP et al (1994) Nuclear matrix proteins in human colon cancer. Proc Natl Acad Sci USA 91:1913

    Article  CAS  PubMed  Google Scholar 

  • Keesee SK, Briggman JV, Thill G et al (1996) Utilization of nuclear matrix proteins for cancer diagnosis. Crit Rev Eukaryot Gene Expr 6:189

    CAS  PubMed  Google Scholar 

  • Khanuja PS, Lehr JE, Soule HD et al (1993) Nuclear matrix proteins in normal and breast cancer cells. Cancer Res 53:3394

    CAS  PubMed  Google Scholar 

  • Kim NW, Piatyszek MA, Prowse KR et al (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011

    Article  CAS  PubMed  Google Scholar 

  • Knowles MA (2007) Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target. World J Urol 25:581

    Article  CAS  PubMed  Google Scholar 

  • Knudson AG Jr (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820

    Article  PubMed  Google Scholar 

  • Knudson AG Jr (1978) Retinoblastoma: a prototypic hereditary neoplasm. Semin Oncol 5:57

    PubMed  Google Scholar 

  • Konety BR (2006) Molecular markers in bladder cancer: a critical appraisal. Urol Oncol 24:326

    CAS  PubMed  Google Scholar 

  • Konety BR, Nangia AK, Nguyen TS et al (1998) Identification of nuclear matrix protein alterations associated with renal cell carcinoma. J Urol 159:1359

    Article  CAS  PubMed  Google Scholar 

  • Konety BR, Nguyen TS, Brenes G et al (2000) Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer. J Urol 164:634

    Article  CAS  PubMed  Google Scholar 

  • Konety BR, Joyce GF, Wise M (2007) Bladder and upper tract urothelial cancer. J Urol 177:1636

    Article  PubMed  Google Scholar 

  • Kouzarides T (2007) Chromatin modifications and their function. Cell 128:693

    Article  CAS  PubMed  Google Scholar 

  • Kramer MW, Golshani R, Merseburger AS et al (2010) HYAL-1 hyaluronidase: A potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer. Eur Urol 57(1):86–93

    Article  CAS  PubMed  Google Scholar 

  • Lee IN, Chen CH, Sheu JC et al (2005) Identification of human hepatocellular carcinoma-related biomarkers by two-dimensional difference gel electrophoresis and mass spectrometry. J Proteome Res 4:2062

    Article  CAS  PubMed  Google Scholar 

  • Lerner SP (2005) Bladder cancer clinical trials. Urol Oncol 23:275

    PubMed  Google Scholar 

  • Li F, Ling X (2006) Survivin study: an update of “what is the next wave”? J Cell Physiol 208:476

    Article  CAS  PubMed  Google Scholar 

  • Li J, Zhao J, Yu X et al (2005) Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid. Clin Cancer Res 11:8312

    Article  CAS  PubMed  Google Scholar 

  • Li J, Gromov P, Gromova I et al (2008) Omics-based profiling of carcinoma of the breast and matched regional lymph node metastasis. Proteomics 8:5038

    Article  CAS  PubMed  Google Scholar 

  • Liang G, Gonzales FA, Jones PA et al (2002) Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2′-deoxycytidine. Cancer Res 62:961

    CAS  PubMed  Google Scholar 

  • Livingstone LR, White A, Sprouse J et al (1992) Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923

    Article  CAS  PubMed  Google Scholar 

  • Lokeshwar VB, Obek C, Pham HT et al (2000) Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade. J Urol 163:348

    Article  CAS  PubMed  Google Scholar 

  • Macadam RC, Sarela AI, Farmery SM et al (2000) Death from early colorectal cancer is predicted by the presence of transcripts of the REG gene family. Br J Cancer 83:188

    Article  CAS  PubMed  Google Scholar 

  • Malkowicz SB (2000) The application of human complement factor H-related protein (BTA TRAK) in monitoring patients with bladder cancer. Urol Clin North Am 27:63

    Article  CAS  PubMed  Google Scholar 

  • Manrow RE, Sburlati AR, Hanover JA et al (1991) Nuclear targeting of prothymosin alpha. J Biol Chem 266:3916

    CAS  PubMed  Google Scholar 

  • Mansoor I, Calam RR, Al-Khafaji B (2008) Role of urinary NMP-22 combined with urine cytology in follow-up surveillance of recurring superficial bladder urothelial carcinoma. Anal Quant Cytol Histol 30:25

    PubMed  Google Scholar 

  • Matin MM, Walsh JR, Gokhale PJ et al (2004) Specific knockdown of Oct4 and beta2-microglobulin expression by RNA interference in human embryonic stem cells and embryonic carcinoma cells. Stem Cells 22:659

    Article  CAS  PubMed  Google Scholar 

  • May M, Hakenberg OW, Gunia S et al (2007) Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice. Urology 70:449

    Article  PubMed  Google Scholar 

  • Menendez V, Fernandez-Suarez A, Galan JA et al (2005) Diagnosis of bladder cancer by analysis of urinary fibronectin. Urology 65:284

    Article  PubMed  Google Scholar 

  • Merlo A, Herman JG, Mao L et al (1995) 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1:686

    Article  CAS  PubMed  Google Scholar 

  • Messing EM, Teot L, Korman H et al (2005) Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States. J Urol 174:1238

    Article  PubMed  Google Scholar 

  • Mian C, Lodde M, Comploj E et al (2005) The value of the ImmunoCyt/uCyt+ test in the detection and follow-up of carcinoma in situ of the urinary bladder. Anticancer Res 25:3641

    PubMed  Google Scholar 

  • Mian C, Lodde M, Comploj E et al (2006) Multiprobe fluorescence in situ hybridisation: prognostic perspectives in superficial bladder cancer. J Clin Pathol 59:984

    Article  CAS  PubMed  Google Scholar 

  • Mitra AP, Datar RH, Cote RJ (2005) Molecular staging of bladder cancer. BJU Int 96:7

    Article  CAS  PubMed  Google Scholar 

  • Mitra AP, Lin H, Datar RH et al (2006) Molecular biology of bladder cancer: prognostic and clinical implications. Clin Genitourin Cancer 5:67

    Article  CAS  PubMed  Google Scholar 

  • Mitra AP, Birkhahn M, Cote RJ (2007) p53 and retinoblastoma pathways in bladder cancer. World J Urol 25:563

    Article  CAS  PubMed  Google Scholar 

  • Mizutani Y, Hongo F, Sato N et al (2001) Significance of serum soluble Fas ligand in patients with bladder carcinoma. Cancer 92:287

    Article  CAS  PubMed  Google Scholar 

  • Modlich O, Prisack HB, Pitschke G et al (2004) Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles. Clin Cancer Res 10:3410

    Article  CAS  PubMed  Google Scholar 

  • Mungan NA, Vriesema JL, Thomas CM et al (2000) Urinary bladder cancer test: a new urinary tumor marker in the follow-up of superficial bladder cancer. Urology 56:787

    Article  CAS  PubMed  Google Scholar 

  • Munro NP, Cairns DA, Clarke P et al (2006) Urinary biomarker profiling in transitional cell carcinoma. Int J Cancer 119:2642

    Article  CAS  PubMed  Google Scholar 

  • Mutlu N, Turkeri L, Emerk K (2003) Analytical and clinical evaluation of a new urinary tumor marker: bladder tumor fibronectin in diagnosis and follow-up of bladder cancer. Clin Chem Lab Med 41:1069

    Article  CAS  PubMed  Google Scholar 

  • Myers-Irvin JM, Van Le TS, Getzenberg RH (2005) Mechanistic analysis of the role of BLCA-4 in bladder cancer pathobiology. Cancer Res 65:7145

    Article  CAS  PubMed  Google Scholar 

  • Nelson AR, Fingleton B, Rothenberg ML et al (2000) Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18:1135

    CAS  PubMed  Google Scholar 

  • Nguyen CT, Jones JS (2008) Defining the role of NMP22 in bladder cancer surveillance. World J Urol 26:51

    Article  CAS  PubMed  Google Scholar 

  • Niwa H, Miyazaki J, Smith AG (2000) Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet 24:372

    Article  CAS  PubMed  Google Scholar 

  • Orenes-Pinero E, Corton M, Gonzalez-Peramato P et al (2007) Searching urinary tumor markers for bladder cancer using a two-dimensional differential gel electrophoresis (2D-DIGE) approach. J Proteome Res 6:4440

    Article  CAS  PubMed  Google Scholar 

  • Ornstein DK, Tyson DR (2006) Proteomics for the identification of new prostate cancer biomarkers. Urol Oncol 24:231

    CAS  PubMed  Google Scholar 

  • Pandey A, Mann M (2000) Proteomics to study genes and genomes. Nature 405:837

    Article  CAS  PubMed  Google Scholar 

  • Pardoll DM, Vogelstein B, Coffey DS (1980) A fixed site of DNA replication in eucaryotic cells. Cell 19:527

    Article  CAS  PubMed  Google Scholar 

  • Prout GR Jr, Barton BA, Griffin PP et al (1992) Treated history of noninvasive grade 1 transitional cell carcinoma. The National Bladder Cancer Group. J Urol 148:1413

    PubMed  Google Scholar 

  • Quek ML, Quinn DI, Daneshmand S et al (2003) Molecular prognostication in bladder cancer – a current perspective. Eur J Cancer 39:1501

    Article  CAS  PubMed  Google Scholar 

  • Raina R, Pahlajani G, Ponsky LE et al (2008) The clinical utility of atypical cytology is significantly increased in both screening and monitoring for bladder cancer when indexed with nuclear matrix protein-22. BJU Int 102:297

    Article  PubMed  Google Scholar 

  • Raitanen MP (2008) The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies. World J Urol 26:45

    Article  PubMed  Google Scholar 

  • Ray JM, Stetler-Stevenson WG (1994) The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J 7:2062

    CAS  PubMed  Google Scholar 

  • Redwood SM, Liu BC, Weiss RE et al (1992) Abrogation of the invasion of human bladder tumor cells by using protease inhibitor(s). Cancer 69:1212

    Article  CAS  PubMed  Google Scholar 

  • Rideout WM 3rd, Coetzee GA, Olumi AF et al (1990) 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science 249:1288

    Article  CAS  PubMed  Google Scholar 

  • Rieger-Christ KM, Mourtzinos A, Lee PJ et al (2003) Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection. Cancer 98:737

    Article  CAS  PubMed  Google Scholar 

  • Rife CC, Farrow GM, Utz DC (1979) Urine cytology of transitional cell neoplasms. Urol Clin North Am 6:599

    CAS  PubMed  Google Scholar 

  • Rosario DJ, Becker M, Anderson JB (2000) The changing pattern of mortality and morbidity from radical cystectomy. BJU Int 85:427

    Article  CAS  PubMed  Google Scholar 

  • Rosner MH, Vigano MA, Ozato K et al (1990) A POU-domain transcription factor in early stem cells and germ cells of the mammalian embryo. Nature 345:686

    Article  CAS  PubMed  Google Scholar 

  • Sakai T, Toguchida J, Ohtani N et al (1991) Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am J Hum Genet 48:880

    CAS  PubMed  Google Scholar 

  • Sanchez-Carbayo M, Socci ND, Lozano J et al (2006) Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 24:778

    Article  CAS  PubMed  Google Scholar 

  • Sangar VK, Ramani VA, George NJ (2008) Should molecular technology replace urine cytology? BJU Int 102:1361

    PubMed  Google Scholar 

  • Sarosdy MF, Hudson MA, Ellis WJ et al (1997) Improved detection of recurrent bladder cancer using the Bard BTA stat Test. Urology 50:349

    Article  CAS  PubMed  Google Scholar 

  • Sarosdy MF, Schellhammer P, Bokinsky G et al (2002) Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 168:1950

    Article  CAS  PubMed  Google Scholar 

  • Sburlati AR, De La Rosa A, Batey DW et al (1993) Phosphorylation of human and bovine prothymosin alpha in vivo. Biochemistry 32:4587

    Article  CAS  PubMed  Google Scholar 

  • Scholer HR, Ruppert S, Suzuki N et al (1990) New type of POU domain in germ line-specific protein Oct-4. Nature 344:435

    Article  CAS  PubMed  Google Scholar 

  • Seligson DB, Horvath S, Shi T et al (2005) Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435:1262

    Article  CAS  PubMed  Google Scholar 

  • Shariat SF, Casella R, Khoddami SM et al (2004) Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 171:626

    Article  CAS  PubMed  Google Scholar 

  • Shariat SF, Karakiewicz PI, Palapattu GS et al (2006) Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 176:2414

    Article  PubMed  Google Scholar 

  • Shariat SF, Ashfaq R, Karakiewicz PI et al (2007) Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer 109:1106

    Article  CAS  PubMed  Google Scholar 

  • Shen H, Cheng G, Fan H et al (2006) Expressed proteome analysis of human hepatocellular carcinoma in nude mice (LCI-D20) with high metastasis potential. Proteomics 6:528

    Article  CAS  PubMed  Google Scholar 

  • Shirodkar SP, Lokeshwar VB (2008) Bladder tumor markers: from hematuria to molecular diagnostics – where do we stand? Expert Rev Anticancer Ther 8:1111

    Article  CAS  PubMed  Google Scholar 

  • Sidransky D, Frost P, Von Eschenbach A et al (1992) Clonal origin bladder cancer. N Engl J Med 326:737

    Article  CAS  PubMed  Google Scholar 

  • Skacel M, Fahmy M, Brainard JA et al (2003) Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 169:2101

    Article  CAS  PubMed  Google Scholar 

  • Smith SD, Wheeler MA, Plescia J et al (2001) Urine detection of survivin and diagnosis of bladder cancer. JAMA 285:324

    Article  CAS  PubMed  Google Scholar 

  • Soderstrom M, Bohling T, Ekfors T et al (2002) Molecular profiling of human chondrosarcomas for matrix production and cancer markers. Int J Cancer 100:144

    Article  CAS  PubMed  Google Scholar 

  • Spruck CH 3rd, Ohneseit PF, Gonzalez-Zulueta M et al (1994) Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 54:784

    CAS  PubMed  Google Scholar 

  • Stein JP, Lieskovsky G, Cote R et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1, 054 patients. J Clin Oncol 19:666

    CAS  PubMed  Google Scholar 

  • Svatek RS, Herman MP, Lotan Y et al (2006) Soluble Fas – a promising novel urinary marker for the detection of recurrent superficial bladder cancer. Cancer 106:1701

    Article  CAS  PubMed  Google Scholar 

  • Tammi RH, Kultti A, Kosma VM et al (2008) Hyaluronan in human tumors: pathobiological and prognostic messages from cell-associated and stromal hyaluronan. Semin Cancer Biol 18:288

    Article  CAS  PubMed  Google Scholar 

  • Tetu B, Tiguert R, Harel F et al (2005) ImmunoCyt/uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma. Mod Pathol 18:83

    Article  CAS  PubMed  Google Scholar 

  • Thievessen I, Seifert HH, Swiatkowski S et al (2003) E-cadherin involved in inactivation of WNT/beta-catenin signalling in urothelial carcinoma and normal urothelial cells. Br J Cancer 88:1932

    Article  CAS  PubMed  Google Scholar 

  • Tornaletti S, Pfeifer GP (1995) Complete and tissue-independent methylation of CpG sites in the p53 gene: implications for mutations in human cancers. Oncogene 10:1493

    CAS  PubMed  Google Scholar 

  • Tzai TS, Tsai YS, Shiau AL et al (2006) Urine prothymosin-alpha as novel tumor marker for detection and follow-up of bladder cancer. Urology 67:294

    Article  PubMed  Google Scholar 

  • van de Rijn M, Gilks CB (2004) Applications of microarrays to histopathology. Histopathology 44:97

    Article  PubMed  Google Scholar 

  • Van Le TS, Miller R, Barder T et al (2005) Highly specific urine-based marker of bladder cancer. Urology 66:1256

    Article  PubMed  Google Scholar 

  • van Rhijn BW, Montironi R, Zwarthoff EC et al (2002) Frequent FGFR3 mutations in urothelial papilloma. J Pathol 198:245

    Article  PubMed  CAS  Google Scholar 

  • van Rhijn BW, Lurkin I, Chopin DK et al (2003) Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine. Clin Cancer Res 9:257

    PubMed  Google Scholar 

  • Vlahou A, Schellhammer PF, Mendrinos S et al (2001) Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 158:1491

    CAS  PubMed  Google Scholar 

  • von Knobloch R, Hegele A, Brandt H et al (2001) Serum DNA and urine DNA alterations of urinary transitional cell bladder carcinoma detected by fluorescent microsatellite analysis. Int J Cancer 94:67

    Article  Google Scholar 

  • Vriesema JL, Atsma F, Kiemeney LA et al (2001) Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence. Urology 58:367

    Article  CAS  PubMed  Google Scholar 

  • Vrooman OP, Witjes JA (2009) Molecular markers for detection, surveillance and prognostication of bladder cancer. Int J Urol 16:234

    Article  CAS  PubMed  Google Scholar 

  • Waddington CH (1939) Preliminary notes on the development of the wings in normal and mutant strains of Drosophila. Proc Natl Acad Sci USA 25:299

    Article  CAS  PubMed  Google Scholar 

  • Wang L, Zhu YF, Guo XJ et al (2005) A two-dimensional electrophoresis reference map of human ovary. J Mol Med 83:812

    Article  CAS  PubMed  Google Scholar 

  • Weber M, Hellmann I, Stadler MB et al (2007) Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 39:457

    Article  CAS  PubMed  Google Scholar 

  • Wittke S, Mischak H, Walden M et al (2005) Discovery of biomarkers in human urine and cerebrospinal fluid by capillary electrophoresis coupled to mass spectrometry: towards new diagnostic and therapeutic approaches. Electrophoresis 26:1476

    Article  CAS  PubMed  Google Scholar 

  • Wittke S, Schiffer E, Bauer HW (2007) Capillary electrophoresis coupled to mass spectrometry for proteome analysis. An innovative diagnostic method for prostate and bladder cancer. Urologe A 46:733

    Article  CAS  PubMed  Google Scholar 

  • Wu TF, Ku WL, Tsay YG (2007a) Proteome-based diagnostics and prognosis of bladder transitional cell carcinoma. Expert Rev Proteomics 4:639

    Article  CAS  PubMed  Google Scholar 

  • Wu G, Guo Z, Chang X et al (2007b) LOXL1 and LOXL4 are epigenetically silenced and can inhibit ras/extracellular signal-regulated kinase signaling pathway in human bladder cancer. Cancer Res 67:4123

    Article  CAS  PubMed  Google Scholar 

  • Wu DL, Zhang WH, Wang WJ et al (2008) Proteomic evaluation of urine from renal cell carcinoma using SELDI-TOF-MS and tree analysis pattern. Technol Cancer Res Treat 7:155

    CAS  PubMed  Google Scholar 

  • Yafi FA, Steinberg JR, Kassouf W (2008) Contemporary management of muscle-invasive bladder cancer. Int J Clin Oncol 13:504

    Article  PubMed  Google Scholar 

  • Yang CH, Lambie EJ, Snyder M (1992) NuMA: an unusually long coiled-coil related protein in the mammalian nucleus. J Cell Biol 116:1303

    Article  CAS  PubMed  Google Scholar 

  • Yoder BJ, Skacel M, Hedgepeth R et al (2007) Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol 127:295

    Article  PubMed  Google Scholar 

  • Yonemura Y, Sakurai S, Yamamoto H et al (2003) REG gene expression is associated with the infiltrating growth of gastric carcinoma. Cancer 98:1394

    Article  CAS  PubMed  Google Scholar 

  • Zachos I, Konstantinopoulos PA, Vandoros GP et al (2009) Predictive value of telomerase reverse transcriptase expression in patients with high risk superficial bladder cancer treated with adjuvant BCG immunotherapy. J Cancer Res Clin Oncol 135(9):1169–1175

    Article  PubMed  Google Scholar 

  • Zhou G, Li H, Gong Y et al (2005) Proteomic analysis of global alteration of protein expression in squamous cell carcinoma of the esophagus. Proteomics 5:3814

    Article  CAS  PubMed  Google Scholar 

  • Zippe C, Pandrangi L, Agarwal A (1999) NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer. J Urol 161:62

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, 600 N. Wolfe St., Marburg 121, Baltimore, MD, 21287, USA

    Robert H. Getzenberg

Authors
  1. Brian K. McNeil
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Obi O. Ekwenna
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert H. Getzenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Miller School of Medicine, Dept. Urology & Cell Biology & Anatomy, University of Miami, NW. 10th Avenue 1400, Miami, 33136, Florida, USA

    Vinata B. Lokeshwar

  2. , Department of Urology and Urologic Oncol, Hannover Medical School, Carl-Neuberg-Str. 1, Hannover, 30625, Germany

    Axel S. Merseburger

  3. Klinik für Urologie und Kinderurologie, Universitätsklinikum Schleswig-Holstein, Arnold-Heller-Str. 7, Kiel, 24105, Germany

    Stefan H. Hautmann

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

McNeil, B.K., Ekwenna, O.O., Getzenberg, R.H. (2011). Molecular Signatures of Bladder Cancer. In: Lokeshwar, V., Merseburger, A., Hautmann, S. (eds) Bladder Tumors:. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-60761-928-4_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-928-4_6

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60761-927-7

  • Online ISBN: 978-1-60761-928-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation